[1] SMADBECK J,PETERSON J F,PEARCE K E,et al.Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma[J].Blood Cancer J,2019,9(12):103.
[2] GRANDRI C,COWLEY S M,JAMES L P,et al.The Myc/Max/Mad network and the transcriptional control of cell behavior[J].Annu Rev Cell Dev Biol,2000,16:653-699.
[3] KUEHL W M,BERGSAGEL P L.MYC addiction:a potential therapeutic target in MM[J].Blood,2012,120:2351-2352.
[4] WALKER B A,WARDELL C P,BRIOLI A,et al.Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients[J].Blood Cancer J,2014,4(3):e191.
[5] ABDALLAH N,BAUGHN B L,RAJKUMAR V S,et al.Implications of MYC rearrangements in newly diagnosed multiple myeloma[J].Clin Cancer Res,2020,26(24):6581-6588.
[6] CHAUHAN A,PAUL R,DEBNATH M,et al.Synthesis of fluorescent binaphthyl amines that bind c MYC G-Quadruplex DNA and repress c-MYC expression[J].J Med Chem,2016,59(15):7275-7281.
[7] KANAZAWA S,SOUCEK L,EVAN G,et al.c-Myc recruits P-TEFb for transcription,cellular proliferation and apoptosis[J].Oncogene,2003,22(36):5707-5711.
[8] JOHANNES B,STEFANIE B,MATTHEW R G,et al.Family matters:How MYC family oncogenes impact small cell lung cancer[J].Cell Cycle,2017,16(16):1489-1498.
[9] YU Q Y,CIEMERYCH M A,SICINSKI P,et al.Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins[J].Oncogene,2005,24(47):7114-7119.
[10] NESBIT C E,TERSAK J M,GROVE L E,et al.Genetic dissection of c-myc apoptotic pathways[J].Oncogene,2000,19(28):3200-3212.
[11] BAUDINO T A,MCKAY C,PENDEVILLE-SAMAIN H,et al.c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression[J].Genes Dev,2002,16(19):2530-2543.
[12] WAHLATROM T,HENRIKSSON M A.Impact of MYC in regulation of tumor cell metabolism[J].Biochem Biophys Acta,2015,1849(5):563-569.
[13] ALLEVATO M,BOLOTIN E,GROSSMAN M,et al.Sequence-specific DNA binding by MYC/MAX to low affinity non E box motifs[J].PLoS One,2017,12(7):e0180147.
[14] GABAY M,LI Y,FELSHER D W.MYC activation is a hallmark of cancer initiation and maintenance[J].Cold Spring Harb Perspect Med,2014,4(6):a014241.
[15] MENSSEN A,EPANCHINTSEV A,LODYGIN D,et al.c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1:Identification of mechanisms underlying c-MYC-induced DNA damage and chromo-somal instability[J].Cell Cycle,2007,6(3):339-352.
[16] ZHOU K G,XU D M,CAO Y,et al.C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma:a meta-analysis of epidemiological studies[J].PLoS One,2014,9(4):e95020.
[17] TU W B,HELANDER S,PILSTAL R,et al.Myc and its interactors take shape[J].Biochim Biophys Acta,2015,1849(5):469-483.
[18] CHEN B J,WU Y L,TANAKA Y,et al.Small molecules targeting C-Myc oncogene:promising anti-cancer therapeutics[J].Int J Biol Sci,2014,10(10):1084-1096.
[19] 魏宇靖,柯波,刘婷婷,等.C-myc基因在慢性粒细胞白血病患者中表达的意义[J].江西医药,2016,51(1):18-20.
[20] CHNG W J,HUANG G F,CHUNG T H,et al.Clinical and biological implications of MYC activation:a common difference between MGUS and newly diagnosed multiple myeloma[J].Leukemia,2011,25(6):1026-1035.
[21] WALKER B A,WARDELL C P,MURISON A,et al.APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma[J].Nat Commun,2015,6:6997.
[22] KYLE R A,RAJKUMAR S V.Multiple myeloma[J].Blood,2008,111(6):2962-2972.
[23] KYLE R A,REMSTEIN E D,THERNEAU T M,et al.Clinical course and prognosis of smoldering(asymptomatic) multiple myeloma[J].N Engl J Med,2007,356(25):2582-1590.
[24] KRISTINE M,NIAMH K,CALEB K S,et al.MYC dysregulation in the progression of multiple myeloma[J].Leukemia,2020,34(1):322-326.
[25] SHOU Y,MARTELLI M L,GABREA A,et al.Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma[J].Proc Natl Acad Sci U S A,2000,97(1):228-233.
[26] MIKULASOVA A,ASHBY C,TYTARENKO R G,et al.Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma[J].Haematologica,2020,105(4):1055-1066.
[27] WALKER B A,WARDELL C P,BRIOLI A,et al.Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prog-nosis in myeloma patients[J].Blood Cancer J,2014,4(3):e191.
[28] SOUCEK L,EVAN G I.The ups and downs of Myc biology[J].Curr Opin Genet Dev,2010,20(1):91-5.
[29] CHNG W J,GONZALEZ-PAZ N,PRICE-TROSKA T,et al.Clinical and biological significance of RAS mutations in multiple myeloma[J].Leukemia,2008,22(12):2280-2284.
[30] AVET-LOISEAU H,ATTAL M,CAMPION L,et al.Long-term analysis of the IFM 99 trials for myeloma:cytogenetic abnormalities[t(4;14),del(17p),1q gains] play a major role in defining long-term survival[J].J Clin Oncol,2012,30:1949-1952.
[31] LUO S Q,XIONG D H,LI J,et al.C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma[J].Oncogene,2020,39(16):3354-3366.
[32] FULCINITI M,AMODIO N,BANDI R L,et al.miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth[J].Blood Cancer J,2016,6(1):e380.
[33] XIAO X C,GU Y L,WANG G J,et al.c-Myc,RMRP,and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma[J].Int J Biol Macromol,2019,122:526-537.
[34] 鹿军,门丽杰,李弹弹,等.miR-451靶向调控c-Myc抑制多发性骨髓瘤RPMI-8226细胞的增殖侵袭和迁移[J].中华肿瘤杂志,2020,42(7):560-564.
[35] MANIER S,POWERS T J,SACCO A,et al.Lin28B/Let-7 axis regulates multiple myeloma proliferation by enhancing c-Myc and ras survival pathways[J].Blood,2013,122(21):273.
[36] AEGALLA S,PIVETTI S,TODOERT K,et al.The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA[J].Nucleic Acids Res,2015,43(10):5182-5193.
[37] SHAFFER A L,EMRE N C,LAMY L,et al.IRF4 addiction in multiple myeloma[J].Nature,2008,454(7201):226-231.
[38] GRIEVE S,WAJNBERG G,LEES M,et al.TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC[J].Blood Adv,2019,3(22):3613-3625.
[39] CRAWFORD J L,CAMPBELL C D,MORGAN J J,et al.The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma[J].Oncogene,2020,39(27):5001-5014.
[40] 万一柯,侯健.复发难治性多发性骨髓瘤治疗的现状与挑战[J].肿瘤防治研究,2019,46(9):759-765.
[41] XIAO R B,CERNY J,DEVITT K,et al.MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance(MGUS)[J].Am J Surg Pathol,2014,38(6):776-783.
[42] BARWICK B G,NERI P,BAHLIS N J,et al.Multiple myeloma immunoglobulin lambda translocations portend poor prognosis[J].Nat Commun,2019,10(1):1911.
[43] SNEAD N M,WU X W,LI A,et al.Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants[J].Nucleic Acids Res,2013,41(12):6209-6221.
[44] MILLER A J,CHANG A,CUNINGHAM P N,et al.Chronic microangiopathy due to DCR-MYC,a myc-targeted short interfering RNA[J].Am J Kidney Dis,2020,75(4):513-516.
[45] JOVANOVI K K,ROCHE-LESTIENNE C,GHOBRIAL I M,et al.Targeting MYC in multiple myeloma[J].Leukemia,2018,32(6):1295-1306.
[46] YAO R S,SUN X Y,XIE Y,et al.Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells[J].Biosci Rep,2018,38(5):BSR20181027.
[47] GAIKWAD M S,PHYO Z,ARTEAGA Q A,et al.A small molecule stabilizer of the MYC G4-Quadruplex induces endoplasmic reticulum stress,senescence and pyroptosis in multiple myeloma[J].Cancers(Basel),2020,12(10):2952.
[48] DENG C C,LIPSTEIN M R,SCOTTO L,et al.Silencing c-Myc translation as a therapeutic strategy through targeting PI3K delta and CK1 epsilon in hematological malignancies[J].Blood,2016,129(1):88-99.
[49] MANIER S,HUYNH D,SHEN Y,et al.Inhibiting the oncogenic translation program is an effectivetherapeutic strategy in multiple myeloma[J].Sci Transl Med,2017,9(389):eaal2668.
[50] ISHIGURO K,KITAJIMA H,NIINUMA T,et al.DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling[J].Haematologica,2019,104(1):155-165.
[51] BISGROVE D A,MAHMOUDI T,HENKLEIN P,et al.Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription[J].Proc Natl Acad Sci U S A,2007,104(34):13690-13695.
[52] BOI M,GAUDIO E,BONETTI P,et al.The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs[J].Clin Cancer Res,2015,21(7):1628-1638.
[53] 时吉祥.BET抑制剂OTX015靶向MYC抗多发性骨髓瘤机制研究[D].苏州:苏州大学,2017.
[54] IMAYOSHI N,YOSHIOKA M,CHAUHAN J,et al.CG13250,a novel bromodomain inhibitor,suppresses proliferation of multiple myeloma cells in an orthotopic mouse model[J].Biochem Biophys Res Commun,2017,484(2):262-268. |
